title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket - Aileron Therapeutics  ( NASDAQ:ALRN ) , Aadi Bioscience  ( NASDAQ:AADI ) ",20231215T131709,https://www.benzinga.com/news/23/12/36255748/why-getaround-shares-are-trading-higher-by-around-86-here-are-20-stocks-moving-premarket,ALRN,0.159043,Neutral,-0.06268
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20241113T180449,https://www.benzinga.com/general/biotech/24/11/41949259/aileron-therapeutics-investigational-drug-shows-encouraging-action-in-lung-fibrosis,ALRN,0.258351,Neutral,0.068011
Are Medical Stocks Lagging Sensus Healthcare  ( SRTS )  This Year?,20240530T134009,https://www.zacks.com/stock/news/2281347/are-medical-stocks-lagging-sensus-healthcare-srts-this-year,ALRN,0.448316,Somewhat-Bullish,0.151897
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights,20240515T211300,https://www.globenewswire.com/news-release/2024/05/15/2882983/28652/en/Aileron-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html,ALRN,0.106659,Neutral,0.074286
"Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics  ( ALRN )  Looks Ripe for a Turnaround",20240507T133505,https://www.zacks.com/stock/news/2269557/down--3629-in-4-weeks-heres-why-aileron-therapeutics-alrn-looks-ripe-for-a-turnaround,ALRN,0.489394,Somewhat-Bullish,0.165799
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million,20240503T200500,https://www.globenewswire.com/news-release/2024/05/03/2875352/28652/en/Aileron-Therapeutics-Announces-Closing-of-Underwritten-Registered-Direct-Offering-of-up-to-Approximately-40-Million.html,ALRN,0.135857,Neutral,0.091173
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20240503T200500,https://www.benzinga.com/pressreleases/24/05/g38623996/aileron-therapeutics-announces-closing-of-underwritten-registered-direct-offering-of-up-to-approxi,ALRN,0.130689,Neutral,0.0893
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20240501T124503,https://www.benzinga.com/pressreleases/24/05/g38549401/aileron-therapeutics-announces-pricing-of-underwritten-registered-direct-offering-priced-at-the-ma,ALRN,0.123951,Neutral,0.09036
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million,20240501T124500,https://www.globenewswire.com/news-release/2024/05/01/2873263/28652/en/Aileron-Therapeutics-Announces-Pricing-of-Underwritten-Registered-Direct-Offering-Priced-At-The-Market-Under-Nasdaq-Rules-of-up-to-Approximately-40-Million.html,ALRN,0.129983,Neutral,0.093706
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis  ( IPF ) ,20240501T123000,https://www.globenewswire.com/news-release/2024/05/01/2873251/28652/en/Aileron-Therapeutics-Announces-Positive-Data-from-Cohort-1-of-the-Phase-1b-Clinical-Trial-of-LTI-03-in-Idiopathic-Pulmonary-Fibrosis-IPF.html,ALRN,0.091162,Neutral,0.053925
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update,20240415T212000,https://www.globenewswire.com/news-release/2024/04/15/2863221/28652/en/Aileron-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html,ALRN,0.102668,Neutral,0.083735
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20240215T210500,https://www.benzinga.com/pressreleases/24/02/g37167884/aileron-therapeutics-and-pulmonary-care-experts-to-discuss-the-potential-implications-of-lti-03-fo,ALRN,0.111358,Neutral,0.057395
"TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development",20240206T120000,https://www.globenewswire.com/news-release/2024/02/06/2824126/0/en/TScan-Therapeutics-Expands-Clinical-Team-with-the-Appointment-of-Dawn-Pinchasik-M-D-M-S-as-Vice-President-Clinical-Development.html,ALRN,0.036926,Neutral,0.045711
"Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 - Aileron Therapeutics  ( NASDAQ:ALRN ) ",20240201T213050,https://www.benzinga.com/pressreleases/24/02/g36899474/aileron-therapeutics-to-host-key-opinion-leader-event-on-february-15-2024,ALRN,0.264897,Somewhat-Bullish,0.172371
"Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024",20240201T213000,https://www.globenewswire.com/news-release/2024/02/01/2822483/28652/en/Aileron-Therapeutics-to-Host-Key-Opinion-Leader-Event-on-February-15-2024.html,ALRN,0.279015,Somewhat-Bullish,0.181639
Aileron Therapeutics Director Awarded $6K Worth of Stock Options - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20231103T150017,https://www.benzinga.com/news/23/11/35593345/aileron-therapeutics-director-awarded-6k-worth-of-stock-options,ALRN,0.52706,Bullish,0.552281
Aileron Therapeutics Board Member Awarded $6K Worth of Stock Options - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20231103T150012,https://www.benzinga.com/news/23/11/35593339/aileron-therapeutics-board-member-awarded-6k-worth-of-stock-options,ALRN,0.522854,Bullish,0.543302
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",20231004T210100,https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,ALRN,0.021778,Neutral,-0.066559
"Top 5 Health Care Stocks That May Collapse In Q2 - Aileron Therapeutics  ( NASDAQ:ALRN ) , Acumen Pharmaceuticals  ( NASDAQ:ABOS ) ",20230510T115329,https://www.benzinga.com/news/23/05/32312863/top-5-health-care-stocks-that-may-collapse-in-q2,ALRN,0.275867,Neutral,-0.014834
"Bears are Losing Control Over Aileron Therapeutics, Inc.  ( ALRN ) , Here's Why It's a 'Buy' Now",20230404T135503,https://www.zacks.com/stock/news/2074297/bears-are-losing-control-over-aileron-therapeutics-inc-alrn-heres-why-its-a-buy-now,ALRN,0.414559,Bullish,0.438377
"Aileron Therapeutics, Inc.  ( ALRN )  Could Find a Support Soon, Here's Why You Should Buy the Stock Now",20230314T135507,https://www.zacks.com/stock/news/2065420/aileron-therapeutics-inc-alrn-could-find-a-support-soon-heres-why-you-should-buy-the-stock-now,ALRN,0.415699,Bullish,0.415262
Looking Into Aileron Therapeutics's Recent Short Interest - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20230303T183207,https://www.benzinga.com/short-sellers/23/03/31195419/looking-into-aileron-therapeuticss-recent-short-interest,ALRN,0.221819,Somewhat-Bullish,0.155473
"S&P 500 Down 2%; Mobilicom Shares Spike Higher - Aileron Therapeutics  ( NASDAQ:ALRN ) , Arbe Robotics  ( NASDAQ:ARBE ) ",20230221T192423,https://www.benzinga.com/news/earnings/23/02/30994277/s-p-500-down-2-mobilicom-shares-spike-higher,ALRN,0.123844,Neutral,-0.130264
Why Aileron Therapeutics  ( ALRN )  Stock Is Plunging Today - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20230221T175027,https://www.benzinga.com/general/biotech/23/02/30989090/aileron-therapeutics-shelves-development-on-chemoprotection-agent-shares-fall,ALRN,0.837089,Bearish,-0.539474
"Dow Tumbles More Than 500 Points; US Manufacturing PMI Rises In February - Aileron Therapeutics  ( NASDAQ:ALRN ) , Arbe Robotics  ( NASDAQ:ARBE ) ",20230221T171033,https://www.benzinga.com/news/earnings/23/02/30992180/dow-tumbles-more-than-500-points-us-manufacturing-pmi-rises-in-february,ALRN,0.123844,Neutral,-0.130264
"Nasdaq Drops Over 100 Points; Walmart Issues Cautious Forecast - Aileron Therapeutics  ( NASDAQ:ALRN ) , Arbe Robotics  ( NASDAQ:ARBE ) ",20230221T151506,https://www.benzinga.com/news/earnings/23/02/30989395/nasdaq-drops-over-100-points-walmart-issues-cautious-forecast,ALRN,0.113866,Neutral,-0.125086
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives,20230221T133000,https://www.globenewswire.com/news-release/2023/02/21/2612166/28652/en/Aileron-Therapeutics-Announces-Termination-of-Phase-1b-Breast-Cancer-Chemoprotection-Trial-and-Exploration-of-Strategic-Alternatives.html,ALRN,0.644385,Neutral,0.037057
"What Makes Aileron Therapeutics, Inc.  ( ALRN )  a New Buy Stock",20221229T170006,https://www.zacks.com/stock/news/2033582/what-makes-aileron-therapeutics-inc-alrn-a-new-buy-stock,ALRN,0.361626,Bullish,0.359944
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20221130T120034,https://www.benzinga.com/pressreleases/22/11/g29902484/aileron-therapeutics-regains-compliance-with-nasdaq-listing-requirements,ALRN,0.514619,Somewhat-Bullish,0.316641
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements,20221130T120000,https://www.globenewswire.com/news-release/2022/11/30/2564828/28652/en/Aileron-Therapeutics-Regains-Compliance-with-Nasdaq-Listing-Requirements.html,ALRN,0.521812,Somewhat-Bullish,0.322141
"Aileron Therapeutics, Inc.  ( ALRN )  May Find a Bottom Soon, Here's Why You Should Buy the Stock Now",20221124T145505,https://www.zacks.com/stock/news/2021878/aileron-therapeutics-inc-alrn-may-find-a-bottom-soon-heres-why-you-should-buy-the-stock-now,ALRN,0.423843,Bullish,0.444223
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split,20221110T130000,https://www.globenewswire.com/news-release/2022/11/10/2553192/28652/en/Aileron-Therapeutics-Announces-a-1-for-20-Reverse-Stock-Split.html,ALRN,0.417053,Somewhat-Bullish,0.255738
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights,20221101T121500,https://www.globenewswire.com/news-release/2022/11/01/2545485/28652/en/Aileron-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Business-Highlights.html,ALRN,0.518618,Neutral,0.085128
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference,20221026T100500,https://www.globenewswire.com/news-release/2022/10/26/2541580/28652/en/Aileron-Therapeutics-Presents-Results-from-Phase-1-Study-in-Healthy-Volunteers-Demonstrating-ALRN-6924-Induced-Cell-Cycle-Arrest-in-Bone-Marrow-Stem-Cells-and-Hair-Follicles-at-EOR.html,ALRN,0.705237,Somewhat-Bullish,0.197619
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 - Aileron Therapeutics  ( NASDAQ:ALRN ) ,20220930T124129,https://www.benzinga.com/pressreleases/22/09/g29093722/aileron-therapeutics-announces-oral-presentation-of-non-clinical-data-demonstrating-alrn-6924-prot,ALRN,0.522333,Somewhat-Bullish,0.208274
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022,20220930T124100,https://www.globenewswire.com/news-release/2022/09/30/2526018/28652/en/Aileron-Therapeutics-Announces-Oral-Presentation-of-Non-Clinical-Data-Demonstrating-ALRN-6924-Protected-Human-Hair-Follicles-and-Their-Stem-Cells-from-Chemotherapy-Induced-Damage-a.html,ALRN,0.519532,Somewhat-Bullish,0.17634
 ( ALRN )  - Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference,20220906T110024,https://www.benzinga.com/pressreleases/22/09/g28753047/aileron-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference,ALRN,0.544495,Somewhat-Bullish,0.291822
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference,20220906T110000,https://www.globenewswire.com/news-release/2022/09/06/2510220/28652/en/Aileron-Therapeutics-to-Present-at-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html,ALRN,0.565345,Somewhat-Bullish,0.300925
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights,20220815T201500,https://www.globenewswire.com/news-release/2022/08/15/2498582/28652/en/Aileron-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Business-Highlights.html,ALRN,0.514619,Somewhat-Bullish,0.180783
Why Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving Premarket,20220805T113501,https://www.benzinga.com/news/22/08/28373054/why-is-marker-therapeutics-trading-higher-by-119-here-are-42-stocks-moving-premarket,ALRN,0.062926,Neutral,-0.012248
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer,20220801T115100,https://www.globenewswire.com/news-release/2022/08/01/2489315/28652/en/Aileron-Therapeutics-Is-Pleased-to-Outline-Strategy-to-Strengthen-Phase-1b-Clinical-Trial-of-ALRN-6924-in-Patients-with-p53-Mutated-Breast-Cancer.html,ALRN,0.569808,Neutral,0.06973
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022,20220708T123106,https://www.benzinga.com/pressreleases/22/07/g27998908/aileron-therapeutics-to-participate-in-fireside-chat-at-the-william-blair-biotech-focus-conference,ALRN,0.501722,Neutral,0.058238
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022,20220708T123100,https://www.globenewswire.com/news-release/2022/07/08/2476580/28652/en/Aileron-Therapeutics-to-Participate-in-Fireside-Chat-at-the-William-Blair-Biotech-Focus-Conference-2022.html,ALRN,0.523063,Neutral,0.105407
Why Aileron Shares Are Falling Today,20220629T134637,https://www.benzinga.com/general/biotech/22/06/27900396/aileron-shares-fall-after-early-data-from-chemoprotective-agent-in-lung-cancer-setting,ALRN,0.887793,Neutral,0.007517
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer  ( NSCLC )  and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer,20220629T103000,https://www.globenewswire.com/news-release/2022/06/29/2471088/28652/en/Aileron-Therapeutics-Announces-Interim-Data-from-Phase-1b-Chemoprotection-Trial-of-ALRN-6924-in-Patients-with-p53-Mutated-Non-Small-Cell-Lung-Cancer-NSCLC-and-Confirms-Development-.html,ALRN,0.493024,Neutral,0.085167
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer,20220519T110000,https://www.benzinga.com/pressreleases/22/05/g27296473/aileron-therapeutics-announces-first-patients-treated-in-phase-1b-trial-of-alrn-6924-in-patients-w,ALRN,0.591306,Neutral,0.078265
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer,20220519T110000,https://www.globenewswire.com/news-release/2022/05/19/2446755/28652/en/Aileron-Therapeutics-Announces-First-Patients-Treated-in-Phase-1b-Trial-of-ALRN-6924-in-Patients-with-p53-Mutated-Neoadjuvant-Breast-Cancer.html,ALRN,0.482315,Neutral,0.060752
"Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022",20220513T110030,https://www.benzinga.com/pressreleases/22/05/g27185424/aileron-therapeutics-to-host-virtual-kol-investor-event-on-may-19-2022,ALRN,0.527457,Neutral,0.070557
"Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022",20220513T110000,https://www.globenewswire.com/news-release/2022/05/13/2442904/28652/en/Aileron-Therapeutics-to-Host-Virtual-KOL-Investor-Event-on-May-19-2022.html,ALRN,0.36475,Neutral,0.045271
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting,20220510T164327,https://www.benzinga.com/pressreleases/22/05/g27116271/aileron-therapeutics-announces-late-breaking-oral-presentation-of-non-clinical-data-demonstrating-,ALRN,0.544495,Neutral,0.094266
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting,20220510T164300,https://www.globenewswire.com/news-release/2022/05/10/2440078/28652/en/Aileron-Therapeutics-Announces-Late-Breaking-Oral-Presentation-of-Non-Clinical-Data-Demonstrating-ALRN-6924-Protected-Human-Hair-Follicles-and-Their-Stem-Cells-from-Chemotherapy-In.html,ALRN,0.503586,Neutral,0.091628
Is Aileron Therapeutics  ( ALRN )  Outperforming Other Medical Stocks This Year?,20220421T134009,https://www.zacks.com/stock/news/1904282/is-aileron-therapeutics-alrn-outperforming-other-medical-stocks-this-year,ALRN,0.729361,Neutral,0.064647
"Is Aileron Therapeutics, Inc.  ( ALRN )  Stock Outpacing Its Medical Peers This Year?",20220405T134009,https://www.zacks.com/stock/news/1893031/is-aileron-therapeutics-inc-alrn-stock-outpacing-its-medical-peers-this-year,ALRN,0.702247,Neutral,0.139742
50 Biggest Movers From Yesterday,20220329T091148,https://www.benzinga.com/news/22/03/26340073/50-biggest-movers-from-yesterday,ALRN,0.074437,Neutral,0.001107
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights,20220328T202000,https://www.globenewswire.com/news-release/2022/03/28/2411402/28652/en/Aileron-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Business-Highlights.html,ALRN,0.50114,Somewhat-Bullish,0.173113
35 Stocks Moving In Monday's Mid-Day Session,20220328T161143,https://www.benzinga.com/news/22/03/26327227/35-stocks-moving-in-mondays-mid-day-session,ALRN,0.103175,Neutral,0.000315
22 Stocks Moving in Monday's Pre-Market Session,20220328T103414,https://www.benzinga.com/markets/penny-stocks/22/03/26316998/22-stocks-moving-in-mondays-pre-market-session,ALRN,0.147501,Neutral,0.000874
64 Biggest Movers From Friday,20220328T080454,https://www.benzinga.com/news/22/03/26315719/64-biggest-movers-from-friday,ALRN,0.060123,Neutral,0.001885
Top Must-Watch Penny Stocks For Your April List,20220325T200640,https://pennystocks.com/featured/2022/03/25/top-must-watch-penny-stocks-april-list/,ALRN,0.094969,Bullish,0.595645
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference,20220322T120430,https://www.benzinga.com/pressreleases/22/03/g26236846/aileron-therapeutics-to-participate-in-maxim-group-2022-virtual-growth-conference,ALRN,0.50156,Neutral,0.063327
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference,20220322T120400,https://www.globenewswire.com/news-release/2022/03/22/2407571/28652/en/Aileron-Therapeutics-to-Participate-in-Maxim-Group-2022-Virtual-Growth-Conference.html,ALRN,0.567024,Neutral,0.110565
